Affinity Biologicals launches Factor VIII, Factor IX Deficient plasma products in Canada, Europe.

M2 PHARMA-September 1, 2014-Affinity Biologicals launches Factor VIII, Factor IX Deficient plasma products in Canada, Europe

(C)2014 M2 COMMUNICATIONS

1 September 2014 - Canadian biological diagnostic and research products maker Affinity Biologicals Inc said Friday it had recently introduced a new range of plasmas, including the Factor VIII Deficient and the Factor IX Deficient plasmas, in Canada and Europe.

The products, cleared by Health Canada and CE-marked, are intended for diagnostic use and hemostasis research.

Specifically, the VisuDep-F Frozen Factor VIII Deficient Plasma is developed to be used as a substrate plasma in the quantitative identification of Factor VIII activity in citrated plasmas using a clot-based assay. The plasma product helps detect FVIII insufficiency for the diagnosis of haemophilia A.

Similarly, the VisuDep-F Frozen Factor IX Deficient Plasma is developed for use as a substrate plasma in the quantitative detection of Factor IX activity in citrated plasmas utilising a clot-based assay. The plasma product identifies low activity of Factor IX for the detection of haemophilia B.

((Comments on this story may be sent to info@m2.com))